Emergent BioSolutions Inc.
EBS
$5.63
-$0.25-4.25%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -18.56% | -0.54% | 2.05% | 2.79% | 21.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.56% | -0.54% | 2.05% | 2.79% | 21.67% |
| Cost of Revenue | -7.40% | -3.05% | -10.07% | -5.26% | -18.99% |
| Gross Profit | -32.56% | 4.24% | 33.65% | 27.37% | 228.42% |
| SG&A Expenses | -22.77% | -16.26% | -9.23% | -8.71% | -1.65% |
| Depreciation & Amortization | 0.62% | -0.76% | -3.42% | 0.00% | 3.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.38% | -9.99% | -0.82% | 2.57% | -4.29% |
| Operating Income | -510.00% | 69.18% | 26.76% | -1.10% | 103.94% |
| Income Before Tax | 88.85% | 80.46% | 76.99% | -7.17% | -48.62% |
| Income Tax Expenses | 919.12% | 62.80% | -2.26% | -85.71% | -62.84% |
| Earnings from Continuing Operations | 76.72% | 74.94% | 73.16% | 2.44% | -43.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.72% | 74.94% | 73.16% | 2.44% | -43.44% |
| EBIT | -510.00% | 69.18% | 26.76% | -1.10% | 103.94% |
| EBITDA | -49.92% | 216.63% | 337.80% | -67.89% | 199.84% |
| EPS Basic | 76.89% | 75.68% | 73.83% | 5.90% | -39.99% |
| Normalized Basic EPS | 67.79% | 57.09% | 30.72% | -2.36% | 73.42% |
| EPS Diluted | 75.41% | 74.97% | 73.16% | 5.95% | -39.98% |
| Normalized Diluted EPS | 57.73% | 55.60% | 28.86% | -2.36% | 73.42% |
| Average Basic Shares Outstanding | 3.73% | 3.67% | 3.55% | 3.89% | 3.30% |
| Average Diluted Shares Outstanding | 6.34% | 4.89% | 4.79% | 3.89% | 3.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |